title: mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.
authors: Tommy
authors: T
authors: Alain
authors: Nahum
authors: N
authors: Sonenberg
authors: Ivan
authors: I
authors: Topisirovic
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015195:Drug Design; D039561:Eukaryotic Initiation Factor-4E / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D039561:Eukaryotic Initiation Factor-4E; D047428:Protein Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases